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1. INTRODUCTION {#mgg31131-sec-0005}
===============

Retinitis pigmentosa (RP; OMIM \# 268000) is a clinically and genetically heterogeneous inherited retinal dystrophy (Huang, Wu, Lv, Zhang, & Jin, [2015](#mgg31131-bib-0024){ref-type="ref"}; Lee & Garg, [2015](#mgg31131-bib-0028){ref-type="ref"}). It is characterized by the progressive loss of rod and cone photoreceptors, which leads to severe visual dysfunction in bilateral eyes (Hartong, Berson, & Dryja, [2006](#mgg31131-bib-0021){ref-type="ref"}). Typical symptoms include progressive night blindness, loss of vision, and tunnel vision. The prevalence of RP is approximately one in 750--9000 individuals (Na et al., [2017](#mgg31131-bib-0034){ref-type="ref"}); RP affects approximately 2.5 million people worldwide (Dias et al., [2018](#mgg31131-bib-0016){ref-type="ref"}). Affected individuals can inherit RP in one of the following patterns: autosomal dominant (adRP, 15%--25%), autosomal recessive (arRP, 5%--20%), X‐linked (xlRP, 5%--15%), or unknown (40%--50%) (Ferrari et al., [2011](#mgg31131-bib-0017){ref-type="ref"}; Lipinski, Thake, & MacLaren, [2013](#mgg31131-bib-0030){ref-type="ref"}; Oishi et al., [2014](#mgg31131-bib-0039){ref-type="ref"}). RP is categorized as either of two types: nonsyndromic or syndromic. Approximately 20%--30% of patients are presumed to exhibit syndromic RP (Dias et al., [2018](#mgg31131-bib-0016){ref-type="ref"}). Variants in genes that are primarily expressed in retinal cells result in nonsyndromic RP; conversely, variants in genes expressed in a variety of cells or tissues lead to syndromic RP (Waters & Beales, [2011](#mgg31131-bib-0051){ref-type="ref"}; Wheway, Parry, & Johnson, [2014](#mgg31131-bib-0052){ref-type="ref"}), such as Usher syndrome or Bardet--Biedl syndrome.

Thus far, 98 genes (33 for syndromic RP and 65 for nonsyndromic RP) and 9 loci (3 for syndromic RP and 6 for nonsyndromic RP) are known to cause RP. More than 3,000 gene variants are responsible for nonsyndromic RP (Guadagni, Novelli, Piano, Gargini, & Strettoi, [2015](#mgg31131-bib-0020){ref-type="ref"}). The underlying molecular etiologies involve the phototransduction cascade and retinal transcription factors associated with the phototransduction cascade, as well as ribonucleic acid splicing machinery, retinal metabolism, retinal cell structure, ciliary structure, and ciliary function (Veleri et al., [2015](#mgg31131-bib-0046){ref-type="ref"}). Most genes associated with RP are expressed in rod photoreceptors, whereas a small number are expressed in retinal pigment epithelium (Koch et al., [2012](#mgg31131-bib-0026){ref-type="ref"}). Next‐generation sequencing (NGS) technology in bioinformatics and computing technologies has undergone rapid development; accordingly, low‐cost, high‐throughput, highly efficient DNA sequencing has enabled accurate diagnosis and precise assessment of patient prognosis. Inherited genetic diseases are increasingly diagnosed accurately using NGS technology (Bamshad et al., [2011](#mgg31131-bib-0005){ref-type="ref"}; Bell et al., [2011](#mgg31131-bib-0006){ref-type="ref"}; Neuhaus et al., [2017](#mgg31131-bib-0035){ref-type="ref"}; Yang et al., [2013](#mgg31131-bib-0055){ref-type="ref"}). However, it remains a considerable challenge to identify disease‐causing genes with NGS technology (Bainbridge et al., [2008](#mgg31131-bib-0004){ref-type="ref"}). Inherited gene variants are reportedly responsible for only 60% of known cases of RP (Huang et al., [2017](#mgg31131-bib-0023){ref-type="ref"}; Xu et al., [2014](#mgg31131-bib-0053){ref-type="ref"}; Zhang, [2016](#mgg31131-bib-0056){ref-type="ref"}); thus, the disease‐causing gene is unknown in a substantial proportion of affected individuals. It is imperative to determine the genetic etiology of RP and provide guidance for efficient molecular diagnosis.

In this study, we enrolled 76 families with syndromic or nonsyndromic RP. All probands were evaluated using NGS technology. Through functional prediction, Sanger sequencing, and segregation analysis, we found that 43 families (56.6%) had disease‐causing variants in 15 genes, while 12 families (15.8%) had only 1 heterozygous variant in 7 arRP genes. We also identified 67 potential pathogenic gene variants, of which 24 have not been previously described.

2. MATERIALS AND METHODS {#mgg31131-sec-0006}
========================

2.1. Ethical compliance {#mgg31131-sec-0007}
-----------------------

The research protocol was approved by the medical ethics committee of Renmin Hospital of Wuhan University and carried out in accordance with the tenets of the Declaration of Helsinki. Written informed consent was obtained from each participant or their guardian (for participants who were children) prior to the study. All participants were consecutively recruited in Renmin Hospital of Wuhan University (Hubei, China), which is located in central China.

2.2. Clinical testing {#mgg31131-sec-0008}
---------------------

A detailed family history was obtained from the proband or the proband\'s family members. All participants received comprehensive ophthalmological examinations, including best‐corrected visual acuity, refractive error measurement, slit lamp examination, intraocular pressure measurement, and funduscopy. Participants who agreed to additional ophthalmological examinations underwent fundus photography, visual field assessment, optical coherence tomography (OCT), and full‐field electroretinography (ERG). High‐resolution fundus photographs were obtained with a digital fundus camera VISUCAM 200 (Carl Zeiss Meditec AG, Jena, Thuringia, Germany). Visual field assessment was performed using a Humphrey HFA II‐750 (Carl Zeiss Meditec AG). OCT was performed using an AngioVue® Imaging System (Optovue). ERG was recorded using an Espion system (Diagnosys) in accordance with the standards and methodology of the International Society for Clinical Electrophysiology of Vision (Mcculloch et al., [2015](#mgg31131-bib-0033){ref-type="ref"}). Participants who exhibited hearing loss or carried gene variants indicative of Usher syndrome underwent hearing examinations using an ITERA sonometer (Otometrics, DK‐2630).

2.3. Targeted panel sequencing and whole exome sequencing {#mgg31131-sec-0009}
---------------------------------------------------------

Genomic DNA was analyzed with targeted panel sequencing (each of six panels containing 70, 316, 78, 370, 429, and 386 genes) or whole exome sequencing (WES). Genes included in the panels are listed in Text [S1](#mgg31131-sup-0007){ref-type="supplementary-material"}; these genes are primarily responsible for inherited retinal dystrophy. Genomic DNA was isolated from leukocytes of venous blood samples using the QIAamp DNA Blood Midi Kit (Qiagen) or TIANamp Blood DNA Midi Kit (TIANGEN Biotech), in accordance with the manufacturer\'s standard protocol. Library preparation was performed using the Ion AmpliseqTM Library Kit 2 or SureSelect Exome V5 Capture library, in accordance with the manufacturer\'s instructions (Biswas et al., [2017](#mgg31131-bib-0009){ref-type="ref"}; Chen et al., [2013](#mgg31131-bib-0014){ref-type="ref"}; Javadiyan et al., [2018](#mgg31131-bib-0025){ref-type="ref"}). Sequencing was performed on an Ion Torrent PGM (Life Technologies) or HiSeq (Illumina) platform.

2.4. Data analysis {#mgg31131-sec-0010}
------------------

The variant nomenclature used in this study complied with the recommendations of the Human Genomic Variation Society (HGVS, <http://www.hgvs.org/>) (Wang et al., [2018](#mgg31131-bib-0048){ref-type="ref"}). Sequence alignments were performed using the Torrent Suite or Burrows‐Wheeler Aligner (Li & Durbin, [2010](#mgg31131-bib-0029){ref-type="ref"}). Variant calling and annotation were conducted in accordance with a previously published protocol (Liu et al., [2015](#mgg31131-bib-0031){ref-type="ref"}; Siggs et al., [2017](#mgg31131-bib-0044){ref-type="ref"}). The raw reads were filtered as clean reads and then aligned to the GRCh37 (hg19) human reference sequence. Variants were preferentially selected for further analysis and validation if they met the following criteria: (a) their minor allele frequency \<0.01 in the 1,000 Genomes Project database (<http://www.internationalgenome.org/>), Exome Aggregation Consortium database (ExAC, <http://exac.broadinstitute.org/>), Genome Aggregation database (gnomAD, <http://gnomad.broadinstitute.org/>), Single Nucleotide Polymorphisms database (dbSNP, <https://www.ncbi.nlm.nih.gov/snp>), and in‐house database with exomes of Chinese individuals; (b) they were nonsynonymous; (c) they were located in exon or intron regions that affected RNA splicing; (d) they were predicted to be damaging or deleterious variants using Polymorphism Phenotyping (PolyPhen2, <http://genetics.bwh.harvard.edu/pph2/>) (Adzhubei et al., [2010](#mgg31131-bib-0002){ref-type="ref"}) and Sorting Intolerant From Tolerant (SIFT, <http://sift.jcvi.org/>) (Kumar, Henikoff, & Ng, [2009](#mgg31131-bib-0027){ref-type="ref"}). Variant annotation in this study complied with the guidelines of the American College of Medical Genetics (ACMG, <https://www.acmg.net/>) (ACMG Board of Directors, [2016](#mgg31131-bib-0001){ref-type="ref"}; Richards et al., [2015](#mgg31131-bib-0040){ref-type="ref"}). Conservation of each amino acid substitution was calculated using PhyloP in Mutation Taster (<http://www.mutationtaster.org/>) (Schwarz, Cooper, Schuelke, & Seelow, [2014](#mgg31131-bib-0042){ref-type="ref"}). A PhyloP value between −14 and +6 was considered indicative of amino acid is conservation among different species. Molecular modeling of wild‐type and mutant protein sequences were computed by a SWISS‐MODEL server homology modeling pipeline that relies on ProMod3, an in‐house comparative modeling engine based on OpenStructure (Bertoni, Kiefer, Biasini, Bordoli, & Schwede, [2017](#mgg31131-bib-0007){ref-type="ref"}; Bienert et al., [2017](#mgg31131-bib-0008){ref-type="ref"}; Waterhouse et al., [2018](#mgg31131-bib-0050){ref-type="ref"}).

2.5. Sanger sequencing and segregation analysis {#mgg31131-sec-0011}
-----------------------------------------------

Raw reads were filtered and the selected variants were subjected to validation and segregation analyses. Polymerase chain reaction was used to amplify gene fragments that included the variants. Primers were designed with Primer3 (<http://primer3.ut.ee/>); primers used for Sanger sequencing are listed in Table [S2](#mgg31131-sup-0005){ref-type="supplementary-material"}. The amplicons were sequenced using 3500xL Dx Genetic Analyser (Applied Biosystems, Foster City, CA, USA) with ABI BigDye Terminator v3.1 Cycle Sequencing kit. The proband sequences and corresponding consensus sequences (obtained from the NCBI Human Genome Database <https://www.ncbi.nlm.nih.gov/>) were analyzed using the SeqMan II software of the Lasergene software package (DNASTAR). DNA samples of all probands and their available family members were subjected to Sanger sequencing and segregation analysis based on the inheritance pattern.

3. RESULTS {#mgg31131-sec-0012}
==========

3.1. Clinical manifestations {#mgg31131-sec-0013}
----------------------------

In total, 76 Chinese families of Han ethnicity were consecutively enrolled in the study. All probands complained of night blindness, constricted vision field, and impaired vision, with the exception of proband 12, who was very young. Four probands who exhibited RP beginning in childhood had complained of strabismus and nystagmus. Most probands exhibited fundus signs typical of RP, including bone spicule pigmentation, retinal vascular stenosis, and waxy‐pale optic disc. The fundus photographs of probands with novel variants are shown in Figure [S1](#mgg31131-sup-0001){ref-type="supplementary-material"}. Visual field analyses showed that probands had a constricted visual field with increased mean deviation. OCT revealed severe thinning of the retinal nerve fiber layer, outer nuclear layer, and epiretinal membranes. Full‐field ERG demonstrated extinguished or severely reduced dark‐adapted and light‐adapted responses, with significant reductions of a and b waves. Typical visual field, OCT, and ERG are shown in Figure [S2](#mgg31131-sup-0002){ref-type="supplementary-material"}. Clinical features of the 43 probands with disease‐causing genes are listed in Table [1](#mgg31131-tbl-0001){ref-type="table"}.

###### 

Clinical features of probands with disease‐causing genes

  No.ID   Gender   Inheritance   Segregation   Clinical manifestations   Age at (year)   BCVA   Fundus Examination   mRNFL (um)   Visual Field (mean deviation)   ERG                              
  ------- -------- ------------- ------------- ------------------------- --------------- ------ -------------------- ------------ ------------------------------- ----- ----- ------- ------- ---- ----
  127     M        AD            Yes           NB, VFD, VD               12              42     FC                   FC           BSPD, ARA, WOD                  195   177   NA      NA      NA   NA
  128     M        AD            NA            NB, VFD, VD               14              42     FC                   HM           BSPD, ARA, WOD                  199   188   NA      NA      NA   NA
  133     F        AD            NA            NB, VFD, VD               6               36     0.2                  0.08         BSPD, ARA, WOD                  137   113   27.12   29.3    NA   NA
  1       M        S             NA            NB, VFD, VD, SNHL         15              21     0.6                  0.6          BSPD, ARA, WOD                  NA    NA    25.47   25.87   NA   NA
  3       M        S             NA            NB, VFD, VD               25              47     0.4                  0.4          BSPD, ARA, WOD                  150   156   26.84   27.49   E    E
  17      M        S             NA            NB, VFD, VD, SNHL         40              59     0.1                  0.12         BSPD, ARA, WOD                  NA    NA    27.65   28.51   E    E
  21      M        S             Yes           NB, VFD, VD, SNHL         14              34     0.6                  0.8          BSPD, ARA, WOD                  183   169   27.08   28.5    NA   NA
  27      M        AR            Yes           NB, VFD, VD, SNHL         13              21     0.8                  0.6          PD, ARA, WOD                    223   211   28.22   27.88   E    E
  37      F        S             NA            NB, VFD, VD               25              44     0.12                 0.05         BSPD, ARA, WOD                  113   132   16.65   18.08   NA   NA
  49      F        S             Yes           NB, VFD, VD, SNHL         4               20     0.6                  0.8          PD, ARA, WOD                    321   350   24.26   25.5    E    E
  67      M        S             NA            NB, VFD, VD, SNHL         20              31     0.1                  0.08         PD, ARA, WOD, MD                168   196   30.54   30.64   E    E
  109     M        S             NA            NB, VFD, VD, SNHL         16              46     0.4                  0.2          BSPD, ARA, WOD                  192   201   25.56   27.89   NA   NA
  113     F        S             Yes           NB, VFD, VD               20              40     HM                   HM           BSPD, ARA, WOD                  189   185   NA      NA      NA   NA
  117     M        S             NA            NB, VFD, VD, SNHL         33              43     0.12                 0.05         BSPD, ARA, WOD                  194   193   27.72   26.49   E    E
  118     M        AR            NA            NB, VFD, VD, SNHL         30              50     0.1                  0.25         BSPD, ARA, WOD                  153   148   NA      NA      NA   NA
  146     F        AR            NA            NB, VFD, VD, SNHL         22              44     LP                   LP           BSPD, ARA, WOD                  NA    NA    NA      NA      NA   NA
  154     M        S             Yes           NB, VFD, VD               20              36     0.6                  0.8          BSPD, ARA, WOD                  209   213   27.8    28.38   E    E
  173     M        AR            Yes           NB, VFD, VD               25              46     HM                   HM           BSPD, ARA, WOD                  NA    NA    NA      NA      E    E
  164     M        AR            Yes           NB, VFD, VD, SNHL         5               40     0.1                  0.12         BSPD, ARA, WOD                  159   162   27.97   28.62   NA   NA
  28      M        S             Yes           NB, VFD, VD               4               26     HM                   HM           TLR, ARA, WOD                   191   188   NA      NA      E    E
  13      M        S             NA            NB, VFD, VD               14              54     LP                   LP           SP, ARA, WOD                    NA    NA    NA      NA      E    E
  55      F        S             Yes           NB, VFD, VD               22              36     0.05                 0.1          SP, ARA, WOD                    215   239   NA      NA      NA   NA
  74      F        S             NA            NB, VFD, VD               40              53     0.5                  0.4          SP, PD, ARA, WOD                175   185   28.1    29.39   E    E
  93      M        S             NA            NB, VFD, VD               25              37     0.3                  0.15         SP, PD, ARA, WOD                194   181   NA      NA      NA   NA
  132     M        AR            NA            NB, VFD, VD               25              56     HM                   LP           SP, PD, ARA, WOD                234   153   NA      NA      NA   NA
  7       M        S             NA            NB, VFD, VD               19              54     0.2                  0.5          BSPD, ARA, WOD                  172   172   29.59   29.14   E    E
  62      F        S             NA            NB, VFD, VD               45              64     FC                   0.12         BSPD, ARA, WOD                  156   187   NA      NA      E    E
  112     M        S             NA            NB, VFD, VD               30              36     0.1                  0.12         BSPD, ARA                       174   195   29.12   30      E    E
  135     M        S             Yes           NB, VFD, VD               8               9      0.6                  0.15         TLR                             NA    NA    29.7    31.64   E    E
  96      M        S             Yes           NB, VFD, VD, N, S         5               25     LP                   HM           BSPD, ARA, WOD                  NA    NA    NA      NA      NA   NA
  143     M        S             Yes           NB, VFD, VD, N, S         5               31     LP                   LP           BSPD, ARA, WOD, MD              NA    NA    NA      NA      NA   NA
  165     M        S             Yes           NB, VFD, VD, N, S         6               28     LP                   LP           BSPD, ARA, WOD                  NA    NA    NA      NA      NA   NA
  16      F        S             Yes           NB, VFD, VD               15              29     0.8                  1            TLR                             254   252   22.02   21.11   E    E
  58      M        S             Yes           NB, VFD, VD               35              55     HM                   HM           BSPD, ARA, WOD                  NA    NA    NA      NA      E    E
  64      F        S             Yes           NB, VFD, VD               35              46     0.1                  0.1          BSPD, ARA, WOD                  159   175   28.43   26.67   E    E
  152     M        S             Yes           NB, VFD, VD               25              37     0.8                  0.8          ARA, TLR                        NA    NA    30.94   31.24   E    E
  168     F        S             Yes           NB, VFD, VD               18              39     0.25                 0.25         BSPD, ARA, WOD                  168   179   27.56   26.45   E    E
  157     F        AR            Yes           NB, VFD, VD, N, S         6               30     HM                   HM           BSPD, ARA, WOD                  NA    NA    NA      NA      NA   NA
  12      M        XL            Yes           VD                        4               7      0.5                  0.5          TLR                             NA    NA    NA      NA      NA   NA
  79      M        S             Yes           NB, VFD, VD, N, S         10              39     LP                   LP           BSPD, ARA, WOD                  NA    NA    NA      NA      NA   NA
  15      M        S             No            NB, VFD, VD               27              37     0.1                  0.3          BSPD, ARA, WOD                  148   146   30.15   30.2    E    E
  68      M        S             NA            NB, VFD, VD               38              51     0.1                  0.1          BSPD, ARA, WOD                  143   154   NA      NA      NA   NA
  176     M        S             No            NB, VFD, VD               8               29     0.1                  0.3          BSPD, ARA, WOD                  170   165   28.04   28.96   E    E

Abbreviations: AD, autosomal dominant; ARA, attenuated retinal arteries; AR, autosomal recessive; BCVA, best‐corrected visual acuity; BSPD, bone spicule pigmentation deposit; E, extinguished; ERG, electroretinography; F, female; FC, finger counting; HM, hand movement; LP, light perception; M, male; MD, macular degeneration; mRNFL, mean retinal nerve fiber layer; N, Nystagmus no; NA, not available; NB, night blindness; OD, right eye; OS, left eye; PD, pigmentation deposit; S, sporadic; S, Strabismus; SNHL, sensorineural hearing loss; SP, salt‐and‐pepper‐like retinal degeneration; TLR, tapetal‐like retinal degeneration; VD, vision decline; VFD, vision field defect; WOD, waxy‐pale optic disc; XL, X‐linked.
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In total, 15 probands harbored *USH2A* (OMIM \* 608400) compound heterozygous or homozygous variants, while 1 proband harbored *CLRN1* (OMIM \* 606397) homozygous variants and 3 probands harbored *USH2A* heterozygous variants. Thirteen probands (11 probands with compound heterozygous or homozygous variants and two probands with *USH2A* heterozygous variants) were diagnosed with Usher syndrome. Six probands (five probands with *USH2A* compound heterozygous or homozygous variants and one proband with *USH2A* heterozygous variants) did not complain of hearing loss and did not exhibit hearing impairment in hearing examinations; they were diagnosed with nonsyndromic RP. Proband 28 had a compound heterozygous *BBS2* (OMIM \* 606151) variant and was diagnosed with Bardet--Biedl syndrome; he exhibited fourth toe brachydactyly in both feet, which was more severe in the right foot. The proband exhibited obesity, with a body mass index of 28.2 kg/m^2^; he refused further examinations (e.g., sperm or genital gland). Notably, he did not exhibit obvious bone spicule pigmentation in the fundus and showed no mental retardation. Five probands with *CYP4V2* (OMIM \* 608614) compound heterozygous or homozygous variants were diagnosed with Bietti crystalline corneoretinal dystrophy. They exhibited typical RP fundus performance with salt‐and‐pepper‐like retinal degeneration.

3.2. NGS results {#mgg31131-sec-0014}
----------------

Based on bioinformatics, Sanger sequencing validation, and segregation analysis, we found that 43 families (56.6%) had disease‐causing variants in 15 genes, including *RHO* (OMIM \* 180380)*, PRPF31* (OMIM \* 606419)*, USH2A, CLRN1, BBS2, CYP4V2, EYS* (OMIM \* 612424)*, RPE65* (OMIM \* 180069)*, CNGA1* (OMIM \* 123825)*, CNGB1* (OMIM \* 600724)*, PDE6B* (OMIM \* 180072)*, MERTK* (OMIM \* 604705)*, RP1* (OMIM \* 603937)*, RP2* (OMIM \* 300757)*,* and *RPGR* (OMIM \* 312610). Segregation analysis was available for 24 of the 43 families, and the variants were segregated with the disease, except for Family 15 and Family 176. Two genes were associated with adRP in three families with heterozygous variants; 11 genes were associated with arRP in 35 families with homozygous variants (10 families) or compound heterozygous variants (25 families); and 2 genes were associated with xlRP in 5 families with hemizygous variants. The gene most frequently found in the study is *USH2A* (19.7%), followed by *CYP4V2* (6.6%). The gene variants of these probands are described in Table [2](#mgg31131-tbl-0002){ref-type="table"}. The genomic information is shown in Table [S3](#mgg31131-sup-0006){ref-type="supplementary-material"}. In addition, we found that 12 families (15.8%) had only one heterozygous variant in seven arRP genes, including *USH2A, EYS, CLRN1, CERKL* (OMIM \* 608381)*, RP1, CRB1* (OMIM \* 604210)*,* and *SLC7A14* (OMIM \* 615720); these heterozygous variants are described in Table [3](#mgg31131-tbl-0003){ref-type="table"}. We did not detect any variants in the remaining 21 families (27.6%). The proportions of genes associated with RP in this cohort are shown in Figure [1](#mgg31131-fig-0001){ref-type="fig"}a.

###### 

Variant information of disease‐causing genes was detected in the study

  **No. ID**   Disease   Panel     Gene     Nucleotide change                       Amino acid change      Variant type   Exon/Intron   Hom/Het/Hem   Polyphen2   SIFT   PhyloP   Reference       ACMG
  ------------ --------- --------- -------- --------------------------------------- ---------------------- -------------- ------------- ------------- ----------- ------ -------- --------------- ------
  127          RP        Panel 2   RHO      c.1045T\>C                              p.(\*349Glnnext\*51)   nonsense       E5            Het           ---         ---    4.658    PMID:24705292   P
  128          RP        WES       RHO      c.1040C\>T                              p.(Pro347Leu)          missense       E5            Het           PrD         D      5.624    PMID:22217031   P
  133          RP        Panel 2   PRPF31   c.220C\>T                               p.(Gln74\*)            nonsense       E3            Het           ---         ---    4.986    PMID:16799052   P
  1            Usher     Panel 1   USH2A    c.538T\>C                               p.(Ser180Pro)          missense       E3            Het           PrD         D      3.592    PMID:19737284   LP
                                   USH2A    c.11714G\>C                             p.(Arg3905Pro)         missense       E61           Het           PrD         D      5.607    Novel           UVS
  3            RP        Panel 3   USH2A    c.142_143insGA                          p.(Lys48Argfs\*98)     insertion      E2            Het           ---         ---    0.524    PMID:30076350   P
                                   USH2A    c.2802T\>G                              p.(Cys934Trp)          missense       E13           Het           PrD         D      0.999    PMID:25356976   LP
  17           Usher     Panel 1   USH2A    c.11156G\>A                             p.(Arg3719His)         missense       E57           Hom           PrD         D      2.111    PMID:28157192   LP
  21           Usher     Panel 3   USH2A    c.4165delG                              p.(Val1389Leufs\*43)   deletion       E19           Het           ---         ---    −0.137   PMID:30076350   LP
                                   USH2A    c.11156G\>A                             p.(Arg3719His)         missense       E57           Het           PrD         D      2.111    PMID:28157192   LP
  27           Usher     Panel 1   USH2A    c.4645C\>T                              p.(Arg1549\*)          nonsense       E22           Het           ---         ---    1.336    PMID:26352687   P
                                   USH2A    c.8559‐2A\>G                            ---                    splice         I42           Het           ---         ---    ‐        PMID:25078356   P
  37           RP        Panel 1   USH2A    c.1397G\>T                              p.(Gly466Val)          missense       E8            Hom           PrD         D      5.667    PMID:24938718   LP
  49           Usher     Panel 2   USH2A    c.656A\>C                               p.(His219Pro)          missense       E4            Het           PoD         D      3.544    Novel           UVS
                                   USH2A    c.11208_11209insT                       p.(Lys3737\*)          insertion      E57           Het           ---         ---    1.194    Novel           LP
  67           Usher     Panel 5   USH2A    c.2017T\>A                              p.(Cys673Ser)          missense       E12           Hom           PrD         D      4.591    Novel           UVS
  109          Usher     WES       USH2A    c.8559‐2A\>G                            ---                    splice         I42           Het           ---         ---    ‐        PMID:25078356   P
                                   USH2A    c.1143G\>C                              p.(Gln381His)          missense       E6            Het           PrD         N      6.022    Novel           UVS
  113          RP        Panel 5   USH2A    c.2802T\>G                              p.(Cys934Trp)          missense       E13           Het           PrD         D      0.999    PMID:25356976   LP
                                   USH2A    c.4616C\>T                              p.(Thr1539Ile)         missense       E21           Het           PrD         N      4.998    PMID:30029497   UVS
  117          Usher     Panel 5   USH2A    c.475C\>T                               p.(Gln159\*)           nonsense       E2            Het           ---         ---    3.108    Novel           LP
                                   USH2A    c.8559‐2A\>G                            ---                    splice         I42           Het           ---         ---    ‐        PMID:25078356   P
  118          Usher     WES       USH2A    c.11156G\>A                             p.(Arg3719His)         missense       E57           Het           PrD         D      2.111    PMID:28157192   P
                                   USH2A    c.8559‐2A\>G                            ---                    splice         I42           Het           ---         ---    ‐        PMID:25078356   P
  146          Usher     Panel 6   USH2A    c.8559‐2A\>G                            ---                    splice         I42           Het           ---         ---    ‐        PMID:25078356   P
                                   USH2A    c.14426C\>T                             p.(Thr4809Ile)         missense       E66           Het           PrD         D      6.161    PMID:18665195   LP
  154          RP        Panel 6   USH2A    c.11156G\>A                             p.(Arg3719His)         missense       E57           Het           PrD         D      2.111    PMID:28157192   LP
                                   USH2A    c.9958G\>T                              p.(Gly3320Cys)         missense       E50           Het           PrD         D      5.589    PMID:25133613   LP
  173          RP        Panel 6   USH2A    c.10588C\>A                             p.(Pro3530Thr)         missense       E54           Het           B           N      0.482    Novel           UVS
                                   USH2A    c.13339A\>G                             p.(Met4447Val)         missense       E63           Het           B           D      1.334    PMID:29625443   UVS
  164          Usher     Panel 6   CLRN1    c.253+6T\>C                             ---                    splice         I1            Hom           ---         ---    ‐        PMID:25356976   LP
  28           RP        Panel 2   BBS2     c.563delT                               p.(Ile188Thrfs\*13)    deletion       E5            Het           ---         ---    3.233    PMID:24608809   P
                                   BBS2     c.1237C\>T                              p.(Arg413\*)           nonsense       E11           Het           ---         ---    2.828    PMID:12920096   P
  13           Bietti    Panel 3   CYP4V2   c.802‐6_810delATACAGGTCATCGCT           ---                    deletion       I6‐E7         Hom           ---         ---    ‐        PMID:30076350   P
  55           Bietti    Panel 2   CYP4V2   c.992A\>C                               p.(His331Pro)          missense       E8            Hom           PrD         D      4.751    PMID:22772592   P
  74           Bietti    Panel 2   CYP4V2   c.802‐6_810delATACAGGTCATCGCT           ---                    deletion       I6‐E7         Het           ---         ---    ‐        PMID:30076350   P
                                   CYP4V2   c.1199G\>A                              p.(Arg400His)          missense       E9            Het           PrD         D      −0.223   PMID:16179904   LP
  93           Bietti    WES       CYP4V2   c.1091‐2A\>G                            ---                    splice         I8            Het           ---         ---    ‐        PMID:25356976   P
                                   CYP4V2   c.802‐8_810delTCATACAGGTCATCGCG/insGC   ---                    indel          I6‐E7         Het           ---         ---    ‐        PMID:23793346   P
  132          Bietti    WES       CYP4V2   c.413G\>A                               p.(Ser138Asn)          missense       E3            Het           PrD         D      0.147    Novel           UVS
                                   CYP4V2   c.992A\>C                               p.(His331Pro)          missense       E8            Het           PrD         D      4.751    PMID:25356976   P
  7            RP        Panel 3   EYS      c.8545C\>T                              p.(Arg2849\*)          nonsense       E43           Het           ---         ---    2.49     PMID:30076350   P
                                   EYS      c.5644+5G\>A                            ---                    splice         I26           Het           ---         ---    ‐        PMID:30076350   P
  62           RP        Panel 1   EYS      c.2953_2961delACTGATGGA                 p.(Thr985_Gly987del)   deletion       E19           Het           ---         ---    0.17     PMID:29159838   LP
                                   EYS      c.8805C\>A                              p.(Tyr2935\*)          nonsense       E43           Het           ---         ---    0.382    PMID:28763560   P
  112          RP        Panel 6   EYS      c.4955C\>A                              p.(Ser1652\*)          nonsense       E26           Het           ---         ---    2.076    PMID:28559085   P
                                   EYS      c.6557G\>A                              p.(Gly2186Glu)         missense       E32           Het           PoD         D      0.561    PMID:25356976   LP
  135          RP        Panel 2   EYS      c.9209T\>C                              p.(Ile3070Thr)         missense       E43           Het           B           N      1.839    PMID:26161267   LP
                                   EYS      c.3489T\>A                              p.(Asn1163Lys)         missense       E23           Het           PrD         D      1.174    PMID:22302105   LP
  96           RP        Panel 1   RPE65    c.131G\>A                               p.(Arg44Gln)           missense       E3            Hom           PrD         D      5.775    PMID:25775262   LP
  143          RP        WES       RPE65    c.725+2T\>A                             ---                    splice         I7            Hom           ---         ---    ‐        Novel           LP
  165          RP        Panel 6   RPE65    c.1379G\>A                              p.(Trp460\*)           nonsense       E13           Het           ---         ---    5.985    Novel           LP
                                   RPE65    c.1403C\>T                              p.(Ser468Leu)          missense       E13           Het           PrD         D      5.985    Novel           UVS
  16           RP        Panel 3   CNGA1    c.829G\>A                               p.(Asp277Asn)          missense       E9            Het           PrD         D      5.52     PMID:30652268   P
                                   CNGA1    c.472delC                               p.(Leu158Phefs\*4)     deletion       E5            Het           ---         ---    2.191    PMID:26496393   P
  58           RP        Panel 4   CNGA1    c.472delC                               p.(Leu158Phefs\*4)     deletion       E5            Hom           ---         ---    2.191    PMID:26496393   P
  64           RP        Panel 4   CNGB1    c.2921T\>G                              p.(Met974Arg)          missense       E29           Hom           PrD         D      3.182    Novel           UVS
  152          RP        Panel 6   PDE6B    c.622G\>A                               p.(Val208Met)          missense       E3            Het           PoD         N      0.065    Novel           UVS
                                   PDE6B    c.2435A\>T                              p.(Asp812Val)          missense       E21           Het           PrD         D      3.971    Novel           UVS
  168          RP        Panel 6   MERTK    c.845‐1G\>A                             ---                    splice         I5            Het           ---         ---    ‐        Novel           P
                                   MERTK    c.1169T\>A                              p.(Val390Asp)          missense       E8            Het           PrD         D      1.547    Novel           LP
  157          RP        Panel 6   RP1      c.4905_4906delGT                        p.(Tyr1636Argfs\*2)    deletion       E4            Het           ---         ---    3.619    Novel           LP
                                   RP1      c.6181delA                              p.(Ile2061Serfs\*12)   deletion       E4            Het           ---         ---    0.277    PMID:30027431   P
  12           RP        Panel 1   RP2      c.409‐411delATT                         p.(Ile137del)          deletion       E2            Hem           ---         ---    4.494    PMID:10937588   P
  79           RP        Panel 1   RP2      c.353G\>A                               p.(Arg118His)          missense       E2            Hem           PrD         D      5.5      PMID:10937588   LP
  15           RP        Panel 2   RPGR     c.2006G\>A                              p.(Trp669\*)           nonsense       E15           Hem           ---         ---    1.007    Novel           LP
  68           RP        WES       RPGR     c.2293delG                              p.(Glu765Argfs\*50)    deletion       E15           Hem           ---         ---    0.138    Novel           LP
  176          RP        Panel 6   RPGR     c.818A\>G                               p.(Gln273Arg)          missense       E8            Hem           PrD         D      4.289    Novel           LP

Abbreviations: B, benign; Bietti, Bietti crystalline corneoretinal dystrophy; D, Deleterious; E, Exon; Hem, hemizygous; Het, heterozygous; Hom, homozygous; I, Intron; LP, Likely pathogenic; N, Neutral; P, pathogenic; PoD, possibly damaging; PrD, probably damaging; RP, retinitis pigmentosa; Usher, Usher syndrome; UVS, uncertain significance; WES, whole exome sequencing.
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###### 

Heterozygous variants with only one hit for autosomal recessive retinitis pigmentosa genes

  No.ID   Disease   Panel     Gene      Nucleotide change   Amino acid change    Variant type   Exon/Intron   Hom/Het/Hem   Polyphen2   SIFT   PhyloP   Reference       ACMG
  ------- --------- --------- --------- ------------------- -------------------- -------------- ------------- ------------- ----------- ------ -------- --------------- ------
  2       Usher     Panel 1   USH2A     c.9815C\>T          p.(Pro3272Leu)       missense       E50           Het           PrD         D      5.593    PMID:18281613   LP
  88      RP        Panel 1   USH2A     c.13465G\>A         p.(Gly4489Ser)       missense       E63           Het           PrD         D      0.735    PMID:29641573   LP
  166     Usher     Panel 6   USH2A     c.5309A\>T          p.(Lys1770Ile)       missense       E27           Het           PrD         N      2.788    Novel           UVS
  45      RP        Panel 1   EYS       c.6416G\>A          p.(Cys2139Tyr)       missense       E31           Het           PrD         D      1.583    PMID:25753737   LP
  77      RP        Panel 2   EYS       c.6416G\>A          p.(Cys2139Tyr)       missense       E31           Het           PrD         D      1.583    PMID:25753737   LP
  84      RP        WES       EYS       c.6557G\>A          p.(Gly2186Glu)       missense       E32           Het           PoD         D      0.561    PMID:25356976   P
  104     RP        Panel 1   EYS       c.9248G\>A          p.(Gly3083Asp)       missense       E43           Het           PrD         N      2.306    PMID:27375351   LP
  30      RP        Panel 1   CLRN1     c.407G\>A           p.(Gly136Glu)        missense       E2            Het           PrD         D      1.197    PMID:27610647   LP
  141     RP        Panel 5   CERKL     c.566delA           p.(Lys189Argfs\*6)   deletion       E3            Het           ---         ---    2.619    Novel           LP
  31      RP        Panel 1   RP1       c.1372A\>T          p.(Arg458\*)         nonsense       E4            Het           ---         ---    0.461    Novel           LP
  73      RP        WES       CRB1      c.2222T\>C          p.(Met741Thr)        missense       E7            Het           PoD         D      2.384    PMID:24535598   LP
  111     RP        Panel 5   SLC7A14   c.524G\>A           p.(Gly175Glu)        missense       E3            Het           PrD         D      5.625    Novel           UVS

Abbreviations: B, benign; Bietti, Bietti crystalline corneoretinal dystrophy; D, Deleterious; E, Exon; Hem, hemizygous; Het, heterozygous; Hom, homozygous; LP, Likely pathogenic; *N*, Neutral; P, pathogenic; PoD, possibly damaging; PrD, probably damaging; RP, retinitis pigmentosa; Usher, Usher syndrome; UVS, uncertain significance; WES, whole exome sequencing.

John Wiley & Sons, Ltd

![Spectrograms of genes and variants for RP probands. (a) Proportions of genes associated with retinitis pigmentosa (RP). (b) Proportions of all types of variants](MGG3-8-e1131-g001){#mgg31131-fig-0001}

In total, we identified 67 potential pathogenic gene variants; these included 38 missense variants (52.2%), 10 nonsense variants (16.4%), 1 small indel variant (1.5%), 10 small deletion variants (14.9%), 2 small insertion variants (3.0%), and 6 splice variants (9.0%). The proportions of all types of variants are shown in Figure [1](#mgg31131-fig-0001){ref-type="fig"}b. Of these 67 potential pathogenic variants, 24 were novel. The pedigrees of the probands with novel variants are shown in Figure [S3](#mgg31131-sup-0003){ref-type="supplementary-material"}; the sequencing chromatographs of novel variants and corresponding wild‐type alleles are shown in Figure [S4](#mgg31131-sup-0004){ref-type="supplementary-material"}. Schematic representations of the genomic structures of genes with novel variants are shown in Figure [2](#mgg31131-fig-0002){ref-type="fig"}a. The eight *USH2A* novel variants were distributed irregularly among the exons of *USH2A*; these variants presumably affect specific domains of the USH2A protein (Figure [2](#mgg31131-fig-0002){ref-type="fig"}b). The topology and molecular models of seven novel variants showed molecular alterations in proteins caused by mutations, except in the *PDE6B* variant c.622G\>A, p.(Val208Met) (Figure [3](#mgg31131-fig-0003){ref-type="fig"}).

![(a) Schematic representations of genomic structures of genes showing locations of novel variants. Numbers below diagram indicate corresponding exon numbers. Parts of exons are omitted. (b) Schematic representation of USH2A protein showing locations of novel variants. Notably, the PDZ‐binding domain in the last section of the schematic representation in green is difficult to identify because it constitutes two amino acids](MGG3-8-e1131-g002){#mgg31131-fig-0002}

![Topology and molecular models of seven novel variants. (a) CYP4V2 protein molecular alteration caused by CYP4V2 variant c.413G\>A, p.(Ser138Asn). These models were predicted using 6c94.1. Compared to the wild‐type model, serine is replaced by aspartic acid, which creates H‐bonds (green dash line) between residues in the mutant model. (b) RPE65 protein molecular alteration caused by RPE65 variant c.1403C\>T p.(Ser468Leu). These models were predicted using 4f30.1. Compared to the wild‐type model, the number of H‐bonds (green dash line) between residues in the mutant model markedly decreased. (c) CNGB1 protein molecular alteration caused by CNGB1 variant c.2921T\>G p.(Met974Arg). These models were predicted using 5h3o.1. Compared to the wild‐type model, the number of H‐bonds (green dash line) between residues in the mutant model markedly decreased. (d) PDE6B protein molecular alteration caused by PDE6B variant c.622G\>A p.(Val208Met). These models were predicted using 6mzb.1. There was no major difference between the wild‐type and mutant models. (e) PDE6B protein molecular alteration caused by PDE6B variant c.2435A\>T, p.(Asp812Val). These models were predicted using 6mzb.1. Compared to the wild‐type model, the last helix is divided in the mutant model. (f) RPGR protein molecular alteration caused by RPGR variant c.818A\>G, p.(Gln273Arg). These models were predicted using 4jhn.1. Compared to the wild‐type model, the number of H‐bonds (green dash line) between residues in the mutant model markedly decreased. (g) SLC7A14 protein molecular alteration caused by SLC7A14 variant c.524G\>A, p.(Gly175Glu). These models were predicted using 6f34.1. Compared to the wild‐type model, glycine is replaced by glutamic acid, which changes the direction of beta strand folding in the mutant model](MGG3-8-e1131-g003){#mgg31131-fig-0003}

4. DISCUSSION {#mgg31131-sec-0015}
=============

Despite the advent of the personalized medicine era, traditional sequencing has not been able to achieve precise genetic diagnosis (Neveling et al., [2013](#mgg31131-bib-0037){ref-type="ref"}). NGS technology is regarded as a powerful and effective tool for the detection of pathogenic gene variants underlying genetic RP (Gilissen, Hoischen, Brunner, & Veltman, [2011](#mgg31131-bib-0019){ref-type="ref"}; Lovric et al., [2014](#mgg31131-bib-0032){ref-type="ref"}; Riera et al., [2017](#mgg31131-bib-0041){ref-type="ref"}; Wang et al., [2019](#mgg31131-bib-0049){ref-type="ref"}). In this study, we used NGS technology, bioinformatics prediction, Sanger sequencing validation, and available family member segregation; we identified 43 families (56.6%) with disease‐causing gene variants, whereas the detection rates were 63.5%, 50%, and 58% in previous studies (Huang et al., [2018](#mgg31131-bib-0022){ref-type="ref"}; Neveling et al., [2012](#mgg31131-bib-0036){ref-type="ref"}; Xu et al., [2015](#mgg31131-bib-0054){ref-type="ref"}). The detection rate of gene variants in patients with RP was higher with targeted panel sequencing and whole exome sequencing than with microarray genotyping (Avila‐Fernandez et al., [2010](#mgg31131-bib-0003){ref-type="ref"}; Blanco‐Kelly et al., [2012](#mgg31131-bib-0010){ref-type="ref"}), targeted‐capture sequencing (Fu et al., [2013](#mgg31131-bib-0018){ref-type="ref"}; Wang et al., [2014](#mgg31131-bib-0047){ref-type="ref"}), or individual gene sequencing (Sweeney, McGee, Berson, & Dryja, [2007](#mgg31131-bib-0045){ref-type="ref"}). In the present study, the detection rates of Usher syndrome, Bardet--Biedl syndrome, and Bietti crystalline corneoretinal dystrophy were 17.1% (13 probands), 1.3% (1 proband), and 6.6% (5 probands), respectively. In these targeted panels, panel 5 was the most informative in Chinese patients with RP due to its relatively high detection rate (71.4%). The detection rate of novel variants among all identified variants was 35.8%, whereas the detection rates were 72.7% and 67% in previous studies (Huang et al., [2018](#mgg31131-bib-0022){ref-type="ref"}; Xu et al., [2014](#mgg31131-bib-0053){ref-type="ref"}). The higher novel detection rate observed in the prior studies was potentially because probands without identified gene variants were enrolled in those studies. The detection rate of variants in *USH2A,* the causative gene most frequently identified in this study, was 19.7% (15 probands). Among families with nonsyndromic RP, variants in *USH2A* were identified in 8.1% (five probands), which was higher than the rate in a study of North American families (7%) (Seyedahmadi, Rivolta, Keene, Berson, & Dryja, [2004](#mgg31131-bib-0043){ref-type="ref"}) and the rate in a study of Spanish families (7%) (Avila‐Fernandez et al., [2010](#mgg31131-bib-0003){ref-type="ref"}). Variants c.8559‐2A\>G and c.11156G\>A in *USH2A* were recurrent, as they were found in five and four probands, respectively. We presume that these variants are founder variants.

In the study, we did not find a disease‐causing variant in 21 families (27.6%), whereas we found only one heterozygous variant of arRP genes in 12 families (15.8%). Possible reasons for these results are as follows. First, targeted panels sequencing and WES cannot capture variants in the noncoding regions of corresponding genes, nor can they detect variants comprising gross deletions, gross insertions, or complex rearrangements (Broadgate, Yu, Downes, & Halford, [2017](#mgg31131-bib-0012){ref-type="ref"}). Second, the sequencing depth of coverage was insufficient to accurately call all variants, especially those located in regions with high GC content. Third, variants of novel genes in patients with RP may have been filtered out in raw data analysis (Daiger, Sullivan, & Bowne, [2013](#mgg31131-bib-0015){ref-type="ref"}). Fourth, other mild and moderate systemic clinical manifestations of syndromic RP may have been neglected (Xu et al., [2014](#mgg31131-bib-0053){ref-type="ref"}). Fifth, small indel, large structural, copy number, or duplication variants in patients with Usher syndrome are not readily identified with NGS technology (Bonnet et al., [2016](#mgg31131-bib-0011){ref-type="ref"}; O\'Donnell‐Luria & Miller, [2016](#mgg31131-bib-0038){ref-type="ref"}). Whole genome sequencing may be a comprehensive alternative strategy because it partially resolves these problems (Carrigan et al., [2016](#mgg31131-bib-0013){ref-type="ref"}).

In this study, we also detected two novel hemizygous *RPGR* variants c.2006G\>A, p.(Trp669\*) and c.818A\>G, p.(Gln273Arg). These variants did not segregate with the disease in family Family 15 and Family 176. Both of the probands' biological parents exhibited wild‐type genotypes without histories of bone marrow transplant surgery. The lack of segregation was possibly because the variants were de novo or because the probands' mothers exhibited chimerism. Other examinations (e.g., high‐depth DNA sequencing of oral mucosa and urinary sediment for somatic cell chimerism, or of an ovum for gonad chimerism) are needed to definitively determine the statuses of the probands' mothers.

This study identified the gene variants in a cohort of Chinese probands with RP; however, there were some limitations. Some panels did not allow analysis of all RP genes. Furthermore, some families could not undergo segregation analysis. We plan to perform WES or whole genome sequencing to capture more genes and include patients in future research.

In conclusion, we enrolled a cohort of 76 families who exhibited RP. We identified 43 families (56.58%) with disease‐causing variants in 15 genes and 12 families (15.79%) with only one heterozygous variant in arRP genes. We also detected 67 potential pathogenic gene variants, of which 24 have not been previously described. These results will provide useful data for clinicians to make accurate genetic diagnosis, prognosis estimation, and genetic counseling; moreover, they will provide further support for researchers to explore RP pathogenesis.
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